Menu Search

Gimv invests in emerging immuno-oncology company ImCheck Therapeutics

Gimv announces a EUR 5 million investment in French ImCheck Therapeutics, an emerging player in the field of cancer and auto-immune immunotherapies that focuses on the development of first-in-class antibodies that activate the immune system against different cancer types. This investment is part of a total Series A financing of EUR 20 million from a consortium of specialized life sciences investors including Kurma, Boehringer Ingelheim Venture Fund (BIVF), Idinvest and Life Science Partners (LSP).